Market closedNon-fractional

Haemonetics/HAE

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Ticker

HAE

Sector

Healthcare

Trading on

NYSE

Industry

Health Care Equipment and Supplies

Headquarters

Boston, United States

Employees

3,657

Haemonetics Metrics

BasicAdvanced
$4.2B
Market cap
36.27
P/E ratio
$2.29
EPS
0.33
Beta
-
Dividend rate
$4.2B
0.33
2.56
1.288
83.083
84.149
10.61%
5.87%
13.22%
36.27
3.22
4.39
-374.96
36.48
12.01%
2.23%
14.57%
13.89%

What the Analysts think about Haemonetics

Analyst Ratings

Majority rating from 7 analysts.
Buy

Haemonetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
5.91% profit margin
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$343M
2.08%
Net income
$20M
-34.94%
Profit margin
5.91%
-36.31%

Haemonetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.98%
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
$1.05
$0.99
$1.04
$0.90
-
Expected
$0.73
$0.89
$0.94
$0.89
$1.01
Surprise
43.74%
11.47%
10.47%
0.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Haemonetics stock?

Haemonetics (HAE) has a market cap of $4.2B as of July 04, 2024.

What is the P/E ratio for Haemonetics stock?

The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 36.27 as of July 04, 2024.

Does Haemonetics stock pay dividends?

No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Haemonetics dividend payment date?

Haemonetics (HAE) stock does not pay dividends to its shareholders.

What is the beta indicator for Haemonetics?

Haemonetics (HAE) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Haemonetics stock

Buy or sell Haemonetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing